Key facts, as of
As of November 2, 2026, Edwards Lifesciences (EW) trades at $92.44, up 12.1% over the past year. Its 52-week range runs from $74.66 to $96.29; the price is 4.0% below that high. It is 29.8% below its all-time high of $131.73, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +189.9%, against +316.3% for the S&P 500 (SPY). It sits 8.2% above its 200-day average of $85.47, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 23.7% annualized, which we rate medium risk. It has a trailing P/E of 55.0. Edwards Lifesciences (EW) has confirmed its next earnings report for November 4, 2026, after the market closes (date from Yahoo Finance, listed on our November 2026 earnings calendar).
Cite: Portfolio Terminal, "Edwards Lifesciences (EW) stock analysis", 2026-11-02. https://portfolio-terminal.com/analyse/ew
Where it trades today
trading 82% of the way up its 52-week range
How the price has moved
How far it is from its record
Edwards Lifesciences (EW) is 29.8% below its all-time high of $131.73, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +189.9%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- EW closes above its 50-day average ($88.20), and the 50-day sits above the 200-day ($85.47): on both averages the chart reads as an uptrend.
- At $92.44, EW is 4.0% below its 1-year high of $96.29, set on July 7, 2026, and 23.8% above its 1-year low of $74.66 (February 11, 2026).
- Over the past month EW rose 8.6%, from $85.15 to $92.44.
- EW trades at 55.0x its last twelve months of earnings and 27.3x the next twelve months' estimate, so analysts expect earnings 101.2% higher.
- Its P/E is 69.0% above the 32.6x median of the 3 other medical devices companies we track (ABT, SYK, BSX).
- EW's 30-day volatility, 23.7% a year, works out to a typical daily move of about 1.5%.
- Yahoo Finance puts its beta at 0.83: over five years of monthly returns, EW moved about 0.83% for each 1% move of the S&P 500.
- The last session traded 2.2x EW's average daily volume of the 30 sessions before it.
What would change the read
- A close under the 50-day average, $88.20 (−4.6% from the last close), would turn the read to a pullback; under the 200-day, $85.47 (−7.5%), the longer rise is in question.
- A close above $96.29 (+4.2%) would be a new 1-year high; below $74.66 (−19.2%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for EW, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under medical devices among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for EW by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for EW. Last refresh: Nov 2, 2026, 7:10 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Medical Devices.
What Edwards Lifesciences does
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a…
What analysts expect
EW carries a buy consensus from 27 analysts, with an average price target of $101.87 versus $92.44 today (+10.2%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
EW generated $6.51B in trailing revenue (13.6% year over year), with a 15.4% net margin, and $1.23B of free cash flow, supported by $3.55B of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $6.07B | $4.73B | $1.64B | $1.07B | $1.84 | $1.33B |
| 2024 | $5.44B | $4.32B | $1.48B | $4.17B | $6.98 | $259.90M |
| 2023 | $5.01B | $4.03B | $1.49B | $1.40B | $2.31 | $629.50M |
| 2022 | $4.46B | $3.74B | $1.54B | $1.52B | $2.46 | $953.40M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
EW is in 18 of the 54 ETFs we track. It weighs most in XLV: 0.78% of the fund, holding #28 of 62.
Famous investors who hold it
EW is in the latest 13F of 1 of the 15 famous investors we follow. Ray Dalio (Bridgewater Associates) holds the most of it: 0.10% of the portfolio, position #163 of 992, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
EW beside the other companies Yahoo Finance files under medical devices among the assets we track (ABT, SYK, BSX, largest first).
EWyou are here$92.44$53.28B
ABTAbbott Laboratories$110.11$190.53B
SYKStryker Corporation$305.71$116.38B
BSXBoston Scientific$44.12$63.94BWhat the chart is saying
In an uptrend, pressing toward $93.43 resistance.
uptrend- Price is 4.8% above its 50-day average and 8.2% above its 200-day.
- RSI at 61 is neither stretched nor washed out.
- The nearest ceiling is $93.43 (+1.1%), the nearest floor $89.26 (-3.4%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is EW valued right now?
Edwards Lifesciences trades at 55.0 times its last twelve months of earnings and 27.3 times the next twelve months' estimate (Yahoo Finance, November 2, 2026). On the chart: in an uptrend, pressing toward $93.43 resistance. Price is 4.8% above its 50-day average and 8.2% above its 200-day.
What is the risk level of EW?
Based on 30-day volatility of 23.7%, EW has MEDIUM risk. Its beta of 0.83 means it has swung less than the S&P 500 over the last five years.
Does EW pay dividends?
Yahoo Finance shows no dividend yield for Edwards Lifesciences (November 2, 2026).
How far is EW from its all-time high?
Edwards Lifesciences is 29.8% below its all-time high of $131.73, reached in December 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +189.9%, against +316.3% for the S&P 500 (SPY).
When does Edwards Lifesciences report earnings?
Edwards Lifesciences (EW) reports its next quarterly earnings on Wednesday, November 4, 2026, after the market closes. The company has confirmed the date; it comes from Yahoo Finance's earnings data and is listed on the Portfolio Terminal November 2026 earnings calendar. For that quarter, the analysts' consensus Yahoo Finance reports is earnings of $0.74 per share.
Which ETFs hold EW?
18 of the 54 popular ETFs we track hold Edwards Lifesciences. The largest weights: XLV (0.78%), VO (0.49%), JEPI (0.26%), RSP (0.20%) and VTV (0.19%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is EW?
0.08%, as of September 30, 2026: EW is holding #220 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.76 in Edwards Lifesciences.
Which famous investors own EW?
Ray Dalio (0.10% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for EW?
The average analyst price target for Edwards Lifesciences (EW) is $101.87 based on 27 analyst estimates, about 10.2% above the current price of $92.44. The published range runs from $84.00 to $117.00.
How much revenue does EW generate?
Edwards Lifesciences reported $6.51B in trailing twelve-month revenue. Revenue growth is running at 13.6% year over year. Net margin sits at 15.4%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare EW with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.